Ayala Pharmaceuticals, Inc. (ADXS)
(Delayed Data from OTC)
$0.25 USD
-0.02 (-7.41%)
Updated Jun 7, 2024 02:16 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Ayala Pharmaceuticals, Inc. [ADXS]
Reports for Purchase
Showing records 61 - 80 ( 96 total )
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Gearing Up for Success; FY1Q15 Update; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Updates on ADXS-HPV Programs at the Investor Day
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive GOG Phase 2 Interim Report Provides Validation for ADXS-HPV; Reiterate Buy
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2015 Preview: Industry Signals Imply Continued Growth
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: RAMAKANTH S
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Advancing with MedImmune PD-L1 Compound
Provider: EQUITIESIQ
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Company Executing On Its Plan; J&J-Aduro Deal Underscores the Advaxis Opportunity
Provider: EQUITIESIQ
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Capital Raise Enables Investors to Be Opportunistic; Balance Sheet Shored Up
Provider: EQUITIESIQ
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
We initiate coverage with an expected 12-month valuation range of $180-$194 million, or between $13 and $14 a share.
Provider: EQUITIESIQ
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Ayala Pharmaceuticals, Inc.
Industry: Medical - Products
Provider: Zacks Investment Research
Analyst: ZENG G